NY-ESO-1 TCR-T cell therapy - Tmunity Therapeutics
Alternative Names: NY-ESO-1 TCR-T triple knockout TCR therapy; NY-ESO-1-redirected CRISPR edited T cells; NYCE T CellsLatest Information Update: 26 Feb 2023
At a glance
- Originator Tmunity Therapeutics
- Developer Parker Hughes Institute; Tmunity Therapeutics; University of Pennsylvania
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma; Multiple myeloma; Myxoid liposarcoma; Synovial sarcoma
Most Recent Events
- 22 Feb 2023 Tmunity Therapeutics has been acquired by Kite Pharma
- 07 May 2020 Discontinued - Phase-I for Malignant melanoma (Second-line therapy or greater) in USA (Parenteral), since the sponsor intends to pursue other targets (NCT03399448)
- 07 May 2020 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (Parenteral), since the sponsor intends to pursue other targets (NCT03399448)